EP1032583A4 - Active immunization against angiogenesis-associated antigens - Google Patents

Active immunization against angiogenesis-associated antigens

Info

Publication number
EP1032583A4
EP1032583A4 EP99911258A EP99911258A EP1032583A4 EP 1032583 A4 EP1032583 A4 EP 1032583A4 EP 99911258 A EP99911258 A EP 99911258A EP 99911258 A EP99911258 A EP 99911258A EP 1032583 A4 EP1032583 A4 EP 1032583A4
Authority
EP
European Patent Office
Prior art keywords
associated antigens
immunization against
active immunization
against angiogenesis
angiogenesis
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP99911258A
Other languages
German (de)
French (fr)
Other versions
EP1032583A1 (en
Inventor
Daniel J Hicklin
Soldano Ferrone
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
New York Medical College
ImClone LLC
Original Assignee
New York Medical College
ImClone Systems Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by New York Medical College, ImClone Systems Inc filed Critical New York Medical College
Publication of EP1032583A1 publication Critical patent/EP1032583A1/en
Publication of EP1032583A4 publication Critical patent/EP1032583A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4615—Dendritic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/462—Cellular immunotherapy characterized by the effect or the function of the cells
    • A61K39/4622—Antigen presenting cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/464454—Enzymes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Cell Biology (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Oncology (AREA)
  • Rheumatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
EP99911258A 1998-03-06 1999-03-08 Active immunization against angiogenesis-associated antigens Withdrawn EP1032583A4 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US3672498A 1998-03-06 1998-03-06
US36724 1998-03-06
PCT/US1999/005164 WO1999045018A1 (en) 1998-03-06 1999-03-08 Active immunization against angiogenesis-associated antigens

Publications (2)

Publication Number Publication Date
EP1032583A1 EP1032583A1 (en) 2000-09-06
EP1032583A4 true EP1032583A4 (en) 2005-02-02

Family

ID=21890263

Family Applications (1)

Application Number Title Priority Date Filing Date
EP99911258A Withdrawn EP1032583A4 (en) 1998-03-06 1999-03-08 Active immunization against angiogenesis-associated antigens

Country Status (4)

Country Link
EP (1) EP1032583A4 (en)
AU (1) AU2994599A (en)
CA (1) CA2310252A1 (en)
WO (1) WO1999045018A1 (en)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002538219A (en) * 1999-03-11 2002-11-12 エントレメッド インコーポレイテッド Compositions and methods for treating cancer and hyperproliferative diseases
FR2796073B1 (en) * 1999-07-07 2003-08-29 Centre Nat Rech Scient ANTI-IDIOTYPIC ANTIBODIES FOR FIBROBLAST GROWTH FACTORS AND THEIR USE AS MEDICAMENTS
US7087592B1 (en) 1999-08-23 2006-08-08 Entre Med, Inc. Compositions comprising purified 2-methoxyestradiol and methods of producing same
US7094410B2 (en) * 2002-03-02 2006-08-22 The Scripps Research Institute DNA vaccine against proliferating endothelial cells and methods of use thereof
CU23178A1 (en) * 2002-04-15 2006-09-22 Ct Ingenieria Genetica Biotech ANTIANGIOGEN ACTIVE ACTIVE IMMUNOTHERAPY
US20040115174A1 (en) * 2002-07-05 2004-06-17 Duke University Angio-immunotherapy
US8399440B2 (en) 2006-03-20 2013-03-19 Entremed, Inc. Disease modifying anti-arthritic activity of 2-methoxyestradiol
WO2008006187A2 (en) * 2006-07-12 2008-01-17 Legeev, Yury V. Protein complexes for prevention and treatment of diseases with angiogenesis disorders
CU24637B1 (en) 2019-12-24 2022-12-12 Ct Ingenieria Genetica Biotecnologia POLYPEPTIDES INCLUDING HUMAN VEGF-A MUTANTS WITH DISULFIDE BRIDGE RE-ARRANGEMENTS AND COMPOSITIONS CONTAINING THEM

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0438803A2 (en) * 1990-01-26 1991-07-31 Immunomedics, Inc. Vaccines against cancer and infectious diseases
WO1994005329A1 (en) * 1992-08-31 1994-03-17 Jenner Technologies Stimulation of an antitumor t-cell response using anti-idiotypic antibodies
WO1997023510A1 (en) * 1995-12-21 1997-07-03 Centre National De La Recherche Scientifique Anti-idiotypic antibodies of vascular endothelial growth factor and use thereof as drugs
WO1997023237A1 (en) * 1995-12-22 1997-07-03 Immunomedics, Inc. Use of immunoconjugates to enhance the efficacy of multi-stage cascade boosting vaccines

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2860875D1 (en) * 1977-09-28 1981-10-15 Nat Res Dev Immunological preparations incorporating mhc antigens and their production
US4778752A (en) * 1983-10-11 1988-10-18 Scripps Clinic And Research Foundation Receptors specific for hapten-modified self proteins
US5703055A (en) * 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
AU651949B2 (en) * 1989-07-14 1994-08-11 American Cyanamid Company Cytokine and hormone carriers for conjugate vaccines
US5965132A (en) * 1992-03-05 1999-10-12 Board Of Regents, The University Of Texas System Methods and compositions for targeting the vasculature of solid tumors
WO1993022343A1 (en) * 1992-05-01 1993-11-11 The Rockfeller University Multiple antigen peptide system having adjuvant properties and vaccines prepared therefrom

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0438803A2 (en) * 1990-01-26 1991-07-31 Immunomedics, Inc. Vaccines against cancer and infectious diseases
WO1994005329A1 (en) * 1992-08-31 1994-03-17 Jenner Technologies Stimulation of an antitumor t-cell response using anti-idiotypic antibodies
WO1997023510A1 (en) * 1995-12-21 1997-07-03 Centre National De La Recherche Scientifique Anti-idiotypic antibodies of vascular endothelial growth factor and use thereof as drugs
WO1997023237A1 (en) * 1995-12-22 1997-07-03 Immunomedics, Inc. Use of immunoconjugates to enhance the efficacy of multi-stage cascade boosting vaccines

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
MARUYAMA HARUHIKO ET AL: "Monoclonal anti-idiotypic antibody functionally mimics the human gastrointestinal carcinoma epitope GA733", INTERNATIONAL JOURNAL OF CANCER, vol. 65, no. 4, 1996, pages 547 - 553, XP008039311, ISSN: 0020-7136 *
ORTEGA N ET AL: "MODULATION DE LA PROGRESSION TUMORALE PAR DES ANTICORPS ANTI-IDIOTYPIQUES DE FACTEURS ANGIOGENIQUES. MODULATION OF TUMOR PROGRESSION BY ANTI-IDIOTYPIC ANTIBODIES OF ANGIOGENIC FACTORS", COMPTES RENDUS DES SEANCES DE L'ACADEMIE DES SCIENCES. SERIE III: SCIENCES DE LA VIE, ELSEVIER, AMSTERDAM, NL, vol. 319, no. 5, 1 May 1996 (1996-05-01), pages 411 - 415, XP000601935, ISSN: 0764-4469 *
PLOUET J ET AL: "VEGF DEPENDENT TUMORAL PROGRESSION: SITMULATION BY ANTI VEGF IDIOTYPIC ANTIBODIES", JOURNAL OF CELLULAR BIOCHEMISTRY. SUPPLEMENT, A.R. LISS, NEW YORK, NY, US, no. SUPPL 18A, January 1994 (1994-01-01), pages 328, XP000602723, ISSN: 0733-1959 *
See also references of WO9945018A1 *

Also Published As

Publication number Publication date
CA2310252A1 (en) 1999-09-10
WO1999045018A1 (en) 1999-09-10
EP1032583A1 (en) 2000-09-06
AU2994599A (en) 1999-09-20

Similar Documents

Publication Publication Date Title
ZA991307B (en) Antibodies against human CD40.
ZA99452B (en) Antibodies against human IL-12.
EP1083926A4 (en) Vaccine
AU9466701A (en) Immunogen
GB9806666D0 (en) Antigen preparation and use
EP1178829A4 (en) Human monoclonal antibody
EP1032583A4 (en) Active immunization against angiogenesis-associated antigens
MXPA02003660A (en) Herbicidal composition and adjuvant.
HUP9800613A3 (en) Humanized antibody against human fas-antigene
GB9822714D0 (en) Vaccines
EP1272205A4 (en) Sialoadhesin factor-2 antibodies
GB0027072D0 (en) Vaccine
AU2001261534A1 (en) The meca-79 antigen and related methods
GB9825184D0 (en) Antigen
GB9929937D0 (en) Antigen delivery
GB9915419D0 (en) Antigens
MXPA01004778A (en) Contraceptive antibody vaccines.
AU6227800A (en) Recombinant antibody directed against human sperm antigen
GB9929923D0 (en) Antigen preparations
GB9800760D0 (en) Antigens
IT1292534B1 (en) PROCEDURE FOR PREPARING AND PACKAGING WUERSTEL.
GB9822143D0 (en) Antigens
GB9819015D0 (en) Antigens
AU2001240424A1 (en) Immunization agent
GB9807805D0 (en) Vaccine

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20000524

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB IE IT LI NL SE

A4 Supplementary search report drawn up and despatched

Effective date: 20041217

17Q First examination report despatched

Effective date: 20080206

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20090707